MedinCell (MEDCL) Aktienübersicht
MedinCell S.A., ein pharmazeutisches Unternehmen, entwickelt in Frankreich lang wirkende injizierbare Arzneimittel in verschiedenen therapeutischen Bereichen. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 6/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 1/6 |
| Dividenden | 0/6 |
MEDCL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MedinCell S.A. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | €25.02 |
| 52-Wochen-Hoch | €39.68 |
| 52-Wochen-Tief | €15.39 |
| Beta | 1.02 |
| 1 Monat Veränderung | -6.36% |
| 3 Monate Veränderung | 13.73% |
| 1 Jahr Veränderung | 48.49% |
| 3 Jahre Veränderung | 275.68% |
| 5 Jahre Veränderung | 168.17% |
| Veränderung seit IPO | 240.41% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 19
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Analysts have nudged their price target for MedinCell slightly higher, from €34.76 to about €35.07. This reflects updated assumptions on fair value, growth, margins, and future P/E, in line with recent upward revisions seen across other covered stocks.Analyseartikel • Jun 17
MedinCell (ENXTPA:MEDCL) Stock Could Be 29.1% Undervalued After UZEDY And Pipeline Progress
Recent updates around MedinCell (ENXTPA:MEDCL) focus on stronger royalty income from UZEDY, progress on its Olanzapine long acting injectable toward a late 2026 US launch, and higher R&D spending that keeps the company in a loss-making phase. See our latest analysis for MedinCell. MedinCell's share price has recently given back some gains, with a 1 day share price return of 12.06% down and a 7 day share price return of 7.23% down. This is despite the 90 day share price return being 20.43% up...Narrativ-Update • Jun 04
MEDCL: Long Acting Schizophrenia Injection Progress Will Support Future Upside
Analysts have adjusted their fair value estimate for MedinCell slightly higher, from €34.28 to €34.76. They cite updated assumptions on discount rates, long term profit margins and future P/E levels as the basis for this revision.Recent updates
Narrativ-Update • Jun 19
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Analysts have nudged their price target for MedinCell slightly higher, from €34.76 to about €35.07. This reflects updated assumptions on fair value, growth, margins, and future P/E, in line with recent upward revisions seen across other covered stocks.Analyseartikel • Jun 17
MedinCell (ENXTPA:MEDCL) Stock Could Be 29.1% Undervalued After UZEDY And Pipeline Progress
Recent updates around MedinCell (ENXTPA:MEDCL) focus on stronger royalty income from UZEDY, progress on its Olanzapine long acting injectable toward a late 2026 US launch, and higher R&D spending that keeps the company in a loss-making phase. See our latest analysis for MedinCell. MedinCell's share price has recently given back some gains, with a 1 day share price return of 12.06% down and a 7 day share price return of 7.23% down. This is despite the 90 day share price return being 20.43% up...Narrativ-Update • Jun 04
MEDCL: Long Acting Schizophrenia Injection Progress Will Support Future Upside
Analysts have adjusted their fair value estimate for MedinCell slightly higher, from €34.28 to €34.76. They cite updated assumptions on discount rates, long term profit margins and future P/E levels as the basis for this revision.Narrativ-Update • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).Narrativ-Update • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).Narrativ-Update • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.Narrativ-Update • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).Narrativ-Update • Feb 25
MEDCL: 2026 Revenue Outlook And New Schizophrenia Drug Will Support Upside
Analysts have kept their price target for MedinCell steady at €35.26, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Teva Pharmaceuticals and MedinCell announced that the U.S. FDA has accepted the New Drug Application for TEV-'749, an olanzapine extended-release injectable suspension for adult schizophrenia treatment, using MedinCell’s SteadyTeq copolymer technology for controlled sustained drug release (Key Developments).Narrativ-Update • Feb 09
MEDCL: 2026 Revenue Guidance Will Support Upside As Profitability Outlook Strengthens
Analysts have trimmed their price target on MedinCell to about €35.26 from roughly €36.16, citing slightly higher discount rate assumptions, modestly softer revenue growth expectations of around 61.5% and a lower projected profit margin of about 70.3%, partly offset by a higher assumed future P/E multiple near 14.5x. What's in the News MedinCell issued revenue guidance for 2026, with expected net sales in a range of $250 million to $280 million.Narrativ-Update • Jan 25
MEDCL: Index Inclusion Will Support Upside As Profitability Outlook Strengthens
Analysts have raised their price target on MedinCell to €36.16 from €35.10, citing updated assumptions that incorporate a higher projected profit margin along with a lower future P/E multiple in their models. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which covers liquid small-cap companies across 23 developed markets, increasing its visibility to global equity investors who track MSCI benchmarks (Key Developments).Narrativ-Update • Jan 11
MEDCL: Index Inclusion Will Support Future Upside Potential
Analysts have raised their price target on MedinCell to €35.10. The latest update reflects adjusted expectations around revenue growth, profit margins and future P/E assumptions.Narrativ-Update • Dec 19
MEDCL: Index Inclusion And New FDA Label Will Drive Upside Potential
Analysts have marginally raised their price target on MedinCell from €34.39 to €35.10, citing slightly stronger long term revenue growth expectations that more than offset a modestly lower projected profit margin and a reduced future P E multiple. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, increasing its visibility among global institutional and index-tracking investors from 24 November 2025 (company announcement).Narrativ-Update • Dec 05
MEDCL: Future Index Inclusion Will Drive Visibility And Earnings Upside Potential
Analysts have modestly reduced their price target for MedinCell by approximately $0.49 per share, reflecting tempered expectations for revenue growth, partially offset by improved projected profit margins and slightly lower future valuation multiples. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, boosting its visibility among global institutional investors and index-tracking funds, effective at the opening of trading on 24 November 2025 (Client Announcement) The FDA has approved UZEDY, a once monthly, subcutaneous long acting risperidone injection using MedinCell’s SteadyTeq technology, for maintenance treatment of bipolar I disorder in adults, expanding its label beyond schizophrenia (Product Related Announcement) MedinCell plans to submit a New Drug Application in the US for Olanzapine LAI, a once monthly long acting injection for schizophrenia using its co polymer technology licensed to Teva, in the fourth quarter of 2025, following positive Phase 3 safety data (Product Related Announcement) UZEDY has received regulatory approval in South Korea and is showing strong commercial traction, with 2024 net sales of 117 million dollars and 95 million dollars already in the first half of 2025.Analyseartikel • Dec 01
MedinCell S.A.'s (EPA:MEDCL) 27% Cheaper Price Remains In Tune With Revenues
MedinCell S.A. ( EPA:MEDCL ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...Narrativ-Update • Nov 21
MEDCL: Index Inclusion Will Drive Increased Visibility And Market Confidence
Analysts have slightly reduced their fair value price target for MedinCell from $35.16 to $34.87, reflecting tempered expectations around revenue growth and profit margins. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which may enhance visibility among institutional investors and index-tracking funds.Narrativ-Update • Nov 06
MEDCL: Profit Margins Are Expected To Improve Significantly With Recent FDA Approval
Analysts have raised their price target for MedinCell from $31.16 to $35.16. This change reflects increased confidence in the company’s future profitability and outlook, even though there is a slightly higher discount rate and moderated revenue growth projections.Narrativ-Update • Oct 23
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
Analysts have raised their price target for MedinCell from €26.90 to €31.16, citing improved revenue growth projections and favorable updates to future earnings expectations as key drivers for this upward revision. What's in the News FDA approves UZEDY, a once-monthly, long-acting risperidone injection, as monotherapy or adjunctive therapy for maintenance treatment of bipolar I disorder in adults.Narrativ-Update • Oct 09
Global Expansion And Extended Patents Will Unlock Future Opportunities
Analysts have raised their price target for MedinCell from $24.47 to $26.90, citing stronger fair value projections and underlying optimism in the company’s financial outlook. What's in the News MedinCell plans to submit a New Drug Application (NDA) for Olanzapine LAI, a once-monthly long-acting treatment for schizophrenia, in the US during the fourth quarter of 2025 (Key Developments).Narrativ-Update • Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47. What's in the News UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.Analyseartikel • Sep 25
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 30...Neues Narrativ • Sep 05
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.Analyseartikel • Jun 19
News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Analyseartikel • Dec 25
Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Analyseartikel • Jul 05
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
The latest analyst coverage could presage a bad day for MedinCell S.A. ( EPA:MEDCL ), with the analysts making...Analyseartikel • Apr 26
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Despite an already strong run, MedinCell S.A. ( EPA:MEDCL ) shares have been powering on, with a gain of 30% in the...Analyseartikel • Jan 09
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 26...Analyseartikel • Mar 02
The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
MedinCell S.A. ( EPA:MEDCL ) shareholders might be concerned after seeing the share price drop 17% in the last month...Analyseartikel • Jan 08
Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Every investor in MedinCell S.A. ( EPA:MEDCL ) should be aware of the most powerful shareholder groups. Large companies...Aktionärsrenditen
| MEDCL | FR Pharmaceuticals | FR Markt | |
|---|---|---|---|
| 7D | 1.5% | -1.0% | -1.2% |
| 1Y | 48.5% | -4.8% | 6.4% |
Rendite im Vergleich zur Industrie: MEDCL übertraf die Branche French Pharmaceuticals , die im vergangenen Jahr eine Rendite von -4.8 erzielte.
Rendite vs. Markt: MEDCL übertraf den Markt French, der im vergangenen Jahr eine Rendite von 6.4 erzielte.
Preisvolatilität
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 2.7% |
Stabiler Aktienkurs: Der Aktienkurs von MEDCL war in den letzten 3 Monaten im Vergleich zum French -Markt volatil.
Volatilität im Zeitverlauf: MEDCLDie wöchentliche Volatilität (8%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der French Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2003 | 145 | Christophe Douat | www.medincell.com |
MedinCell S.A., ein pharmazeutisches Unternehmen, entwickelt in Frankreich lang wirkende injizierbare Arzneimittel in verschiedenen therapeutischen Bereichen. Es entwickelt Lösungen auf der Grundlage von BEPO, einer Technologie für langwirksame Injektionspräparate, und bietet UZEDY (mdc-IRM) für die Behandlung von Schizophrenie bei Erwachsenen an. Zu den in der Entwicklung befindlichen Produkten des Unternehmens gehören mdc-CWM, eine Formulierung von Celecoxib mit verzögerter Wirkstofffreisetzung, die sich in Phase-III-Studien zur Behandlung von postoperativen Schmerzen und Entzündungen befindet, sowie mdc-TJK, eine subkutane Injektion, die sich in klinischen Studien der Phase III zur Behandlung von Schizophrenie befindet.
MedinCell S.A.'s Grundlagenzusammenfassung
| MEDCL grundlegende Statistiken | |
|---|---|
| Marktanteil | €898.32m |
| Gewinn(TTM) | -€19.95m |
| Umsatz(TTM) | €32.44m |
27.7x
Kurs-Umsatz-Verhältnis-45.0x
Kurs-Gewinn-Verhältnis Ist MEDCL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MEDCL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | €32.44m |
| Kosten der Einnahmen | €0 |
| Bruttogewinn | €32.44m |
| Sonstige Ausgaben | €52.39m |
| Gewinn | -€19.95m |
Zuletzt gemeldete Gewinne
Sep 30, 2025
Datum des nächsten Gewinnberichts
Dec 08, 2026
| Gewinn per Aktie (EPS) | -0.56 |
| Bruttomarge | 100.00% |
| Nettogewinnspanne | -61.49% |
| Schulden/Eigenkapital-Verhältnis | -232.2% |
Wie hat sich MEDCL auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/24 08:25 |
| Aktienkurs zum Tagesende | 2026/06/24 00:00 |
| Gewinne | 2025/09/30 |
| Jährliche Einnahmen | 2025/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
MedinCell S.A. wird von 12 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Seynnaeve | Degroof Petercam |
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |